JOURNAL OF BIOCHEMICAL SCIENCES
Jan-June 2025, VOL. 2, ISSUE 1, pp. 12-15
https://doi.org/10.61577/jbs.2025.100004

RESEAPRO JOURNALS

REVIEW

OPEN ACCESS

Navigating the network: a review of metabolic pathways and their roles in cellular homeostasis and disease

Swati Suman Mishra and Supriya Mohanty

Department of Biotechnology, Mits School of Biotechnology, Bhubaneswar, Odisha, India

ABSTRACT

Metabolic pathways are the carefully coordinated series of chemical reactions that sustain life within every living cell. These pathways convert food and other molecules into energy and building blocks needed for growth, repair, and function. Broadly, metabolism consists of catabolic pathways, which break down complex molecules to release energy, and anabolic pathways, which use that energy to construct essential compounds like proteins and DNA. A third type, amphibolic pathways, can function in either direction depending on the cell's needs. These reactions do not occur randomly but follow precise routes regulated by enzymes, energy demands, and internal feedback mechanisms. For example, when energy is abundant, cells store it; when scarce, they release it through highly efficient processes like glycolysis and the citric acid (Krebs) cycle. Compartmentalization of these pathways inside cellular structures like mitochondria and the cytosol allows for greater control and specialization. Disruptions or alterations in these pathways are closely linked to diseases like cancer, diabetes, and metabolic disorders. Cancer cells, for instance, often rewire their metabolism to consume nutrients differently, making these pathways attractive targets for modern therapies. Emerging treatments are already exploiting this, using drugs that disrupt key enzymes in energy generation or nutrient absorption. Metabolic engineering also enables the design of microbes to produce drugs or chemicals sustainably, as seen in the lab-based biosynthesis of complex cancer drugs. Understanding these pathways is essential not just for biologists but also for clinicians, pharmacologists, and biotechnologists aiming to manipulate metabolism for therapeutic or industrial benefit.

KEY WORDS

Metabolic pathways; Catabolic and anabolic processes; Enzyme regulation; Compartmentalization; Metabolic disorders

ARTICLE HISTORY

Received 15 April 2025; Revised 21 May 2025; Accepted 5 June 2025

Introduction

At the heart of every living cell is a bustling network of chemical reactions that work like an intricate factory to keep life running. These reactions don't occur randomly they follow well-organized routes known as metabolic pathways [1]. Each pathway is a sequence of step-by-step reactions, where one chemical is transformed into another through the help of specialized proteins called enzymes. These transformations are essential for cells to extract energy from nutrients, build new cellular components, and remove waste. Metabolic pathways can be broadly grouped into two categories: catabolic and anabolic [2]. Catabolic pathways are like cellular recycling plants. They break down large, complex molecules like sugars, fats, or proteins into smaller ones, releasing energy in the process. This energy is captured in molecular "batteries" like ATP (adenosine triphosphate) and NADH, which power everything from muscle contraction to DNA replication. One familiar example of a catabolic pathway is glycolysis, where glucose (a sugar) is broken down to produce energy.

On the other hand, anabolic pathways build new molecules from smaller components. Think of them as construction sites. They use the energy produced by catabolic pathways to assemble proteins from amino acids, DNA from nucleotides, or fats for energy storage [3,4]. These two systems catabolism and anabolism are tightly linked, forming a finely balanced cycle that keeps the cell functioning smoothly. Some pathways, like the citric acid cycle, play both roles and are called amphibolic. These dual-purpose routes adapt depending on whether the cell needs to produce energy or build molecules. Importantly, these processes don't occur in isolation [5]. They're influenced by factors such as nutrient availability, energy demand, and signals from hormones or the environment. As such, they are heavily regulated through complex feedback mechanisms.

In human health, metabolic pathways are more than just background processes—they play a central role in diseases. For instance, cancer cells often reprogram their metabolism to fuel rapid growth. Diabetes arises when metabolic regulation of blood sugar fails. Even conditions like obesity, heart disease, and neurodegeneration trace back to shifts in metabolism [6,7]. Modern research is now using powerful tools to map these pathways, understand how they work, and identify how they go wrong in disease. This includes techniques like metabolomics, genetic knockouts, and computational modeling. Insights from this field are opening doors to new treatments whether by blocking faulty pathways in cancer or enhancing healthy metabolism in chronic disease. In essence, understanding metabolic pathways isn't just for biochemists—it's fundamental to modern medicine, biotechnology, and disease therapy [8]. This review aims to explore the core principles, key pathways, regulation mechanisms, and emerging therapeutic strategies rooted in metabolism.

Classification and Regulation of Metabolic Pathways

Metabolic pathways are primarily classified based on the direction and function of their biochemical reactions [9].

***Correspondence:** Swati Suman Mishra, Mits School of Biotechnology, Bhubaneswar, Odisha, India, e-mail: swatisuman0061@gmail.com

These classifications not only reflect the nature of the transformations occurring but also inform how energy and molecular building blocks are managed within the cell.

Catabolic pathways: energy-releasing routes

Catabolic pathways are exergonic sequences of reactions that break down complex molecules such as carbohydrates, lipids, and proteins into simpler molecules, releasing stored chemical energy [10]. This energy is captured in high-energy intermediates like ATP, NADH, and $FADH_2$. A classic example is glycolysis, where glucose is broken down into pyruvate, producing a net gain of ATP:

$$Glucose+2ADP+2Pi+2NAD^+\rightarrow 2Pyruvate+2ATP+2NADH+2H_2O$$

Another central catabolic process is the tricarboxylic acid (TCA) cycle, which oxidizes acetyl-CoA to CO_2 while generating reducing equivalents:

$$Acetyl\text{-}CoA+3NAD^++FAD+GDP+Pi\rightarrow 2CO_2+3NADH+FADH_2+GTP+CoA$$

These reducing agents then feed electrons into the electron transport chain (ETC), leading to ATP synthesis via oxidative phosphorylation.

Anabolic pathways: biosynthetic routes

In contrast, anabolic pathways are endergonic, consuming energy to synthesize complex macromolecules such as nucleic acids, proteins, and lipids from simpler precursors. These reactions require the input of ATP and reducing equivalents like NADPH [11]. A classic anabolic example is gluconeogenesis, which synthesizes glucose from non-carbohydrate precursors like lactate or amino acids:

$$2Pyruvate+4ATP+2GTP+2NADH+6H_2O\rightarrow Glucose+4ADP+2GDP+6Pi+2NAD^+$$

These pathways often occur in different cellular compartments (e.g., gluconeogenesis in the liver cytosol and mitochondria), ensuring separation from catabolic reactions and avoiding futile cycles.

Amphibolic pathways: dual functional role

Some pathways, such as the citric acid cycle, serve both anabolic and catabolic roles, and are hence termed amphibolic. They degrade acetyl-CoA to provide energy (catabolic) but also supply intermediates for biosynthesis, such as α-ketoglutarate for amino acid production (anabolic) [12]. This dual functionality allows dynamic resource allocation in response to cellular needs.

Regulation of Metabolic Pathways

Regulation of metabolic pathways is essential to maintain homeostasis, prevent resource waste, and ensure appropriate responses to environmental and intracellular signals. The most common regulatory mechanisms include:

Allosteric Regulation: Metabolites bind non-covalently to enzymes and alter activity. For example, ATP acts as an allosteric inhibitor of phosphofructokinase-1 (PFK-1) in glycolysis.

Feedback Inhibition: The end-product of a pathway inhibits an upstream enzyme. In purine biosynthesis, AMP and GMP inhibit their respective pathways.

Covalent Modification: Enzymes can be activated or inactivated by phosphorylation (e.g., glycogen phosphorylase activation by protein kinase A).

Compartmentalization: Distinct pathways are segregated within organelles (e.g., fatty acid oxidation in mitochondria vs. synthesis in cytosol).

Gene Expression Regulation: Long-term adaptation to metabolic demands is achieved by upregulating or downregulating gene expression (e.g., insulin increases transcription of glycolytic enzymes).

The rate-limiting step in a pathway often serves as the key regulatory point [13]. For instance, the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate, catalyzed by PFK-1, is highly regulated due to its irreversible and committed nature in glycolysis [14].

$$Fructose\text{-}6\text{-}Phosphate+ATP\rightarrow Fructose\text{-}1,6\text{-}Bisphosphate+ADP$$

The classification and regulation of metabolic pathways form the foundation for understanding cellular energy balance, biosynthesis, and response to physiological stress. These systems are not static but highly adaptable, responding to nutrient status, hormonal cues, and developmental needs making them prime targets in both research and therapeutic intervention[15].



Figure 1. Overview of major cellular metabolic pathways showing the interaction between catabolic and anabolic routes via the citric acid cycle and ATP production.



Figure 2. Visualization of compartmentalized metabolism in a eukaryotic cell showing how different organelles specialize in distinct biochemical processes like glycolysis, protein synthesis, and lipid metabolism.

https://doi.org/10.61577/jbs.2025.100004



Figure 3. Overview of key metabolic pathways in a eukaryotic cell showing glycolysis, gluconeogenesis, the citric acid cycle, and oxidative phosphorylation with directional flow, energy outputs, and regulatory inhibition points.

Pathways in Disease and Therapy

Metabolic pathways are intricately tied to disease processes, particularly in cancer, where they undergo profound reprogramming to support uncontrolled growth. One of the most recognized alterations is the Warburg effect, where tumor cells preferentially utilize aerobic glycolysis over oxidative phosphorylation (OXPHOS), even in the presence of ample oxygen [16]. This shift allows cancer cells to rapidly generate ATP and biosynthetic precursors, fueling proliferation and survival. Targeting these metabolic shifts has become a promising avenue for anticancer therapy. One approach involves inhibiting OXPHOS, the mitochondrial energy-production machinery that remains active in many cancers, particularly in cancer stem cells and therapy-resistant tumors. Drugs such as lonidamine (Complex II inhibitor) and atovaquone (Complex III inhibitor) disrupt the electron transport chain (ETC), impair ATP synthesis, and induce metabolic stress in cancer cells [17]. These inhibitors reduce the proton gradient across the mitochondrial membrane, halting the activity of ATP synthase and triggering apoptotic pathways.

Another key target is glutaminolysis, a pathway that cancer cells rely on for nitrogen balance and redox homeostasis. The enzyme glutaminase (GLS) catalyzes the first step in converting glutamine to glutamate, which feeds into the TCA cycle [18]. Inhibitors like CB-839 (telaglenastat) and azaserine selectively block GLS, starving tumor cells of crucial intermediates. CB-839 has shown promising results in clinical trials across several cancers, including renal, triple-negative breast, and non-small cell lung cancers. Overall, these strategies exemplify a shift toward metabolic precision oncology, where disrupting cancer-specific energy and biosynthetic pathways holds therapeutic potential [19]. By exploiting the metabolic vulnerabilities of tumors, these treatments may offer improved efficacy and reduced toxicity compared to conventional cytotoxic drugs. Continued research is essential to unravel metabolic heterogeneity across cancers and develop combination therapies that target multiple nodes within the metabolic network.



Figure 4. Comparison of cancer and normal cell metabolism highlighting the Warburg effect, glycolysis, lactate production, and differences in oxidative phosphorylation and ATP yield.

Future Directions and Perspective

As the understanding of metabolic pathways deepens, the field is entering a transformative phase with significant implications for diagnostics, therapeutics, and precision medicine. In the future, metabolic reprogramming is expected to become a key hallmark not just in cancer but across a broader spectrum of diseases including neurodegenerative disorders, cardiovascular conditions, and immune dysfunctions [20]. One major direction is the integration of systems biology and metabolomics. With advances in high-throughput technologies like mass spectrometry and NMR spectroscopy, researchers are now capable of mapping dynamic changes in metabolite fluxes in real-time. This opens new opportunities for metabolic profiling as a diagnostic tool identifying disease states, monitoring therapy, and even predicting drug responses.

Another promising area is therapeutic metabolic targeting. As metabolic dependencies differ across tumor types and even within subpopulations of cancer cells, personalized metabolic therapy tailoring inhibitors of glycolysis, glutaminolysis, or mitochondrial respiration holds great promise. Drugs such as CB-839, ivosidenib, and atovaquone are only the beginning [21]. The next generation of therapies will likely involve combinatorial approaches targeting multiple pathways, possibly in tandem with immunotherapies. In the realm of synthetic biology, rewiring metabolic pathways in microorganisms to produce pharmaceuticals, biofuels, or rare biochemicals is gaining traction. Pathway engineering, when combined with CRISPR and AI-driven optimization, may redefine industrial biotechnology.

However, challenges remain. Metabolic plasticity the ability of cells to switch pathways can lead to drug resistance. Additionally, metabolic targeting must balance efficacy with safety, as many of the same pathways are critical for normal cell function. Therefore, deeper exploration into tissue-specific metabolism, non-canonical metabolic routes, and cross-talk with signaling pathways is crucial. Looking ahead, the convergence of computational modeling, AI, and experimental metabolomics will likely enable predictive simulations of cellular metabolism. These models will not only facilitate drug discovery but also help unravel the complex, nonlinear behavior of biological systems under stress or disease. The study of metabolic pathways is evolving from a descriptive science to a highly strategic domain of intervention. By decoding the chemical logic of life, researchers are poised to shift paradigms in medicine, agriculture, and biotechnology turning metabolic insights into actionable, life-saving solutions.

https://doi.org/10.61577/jbs.2025.100004

Conclusions

Metabolic pathways form the foundational blueprint of cellular life, orchestrating the breakdown and synthesis of biomolecules to maintain energy balance, growth, and survival. The classification into catabolic, anabolic, and amphibolic routes provides a clear framework to understand how cells adapt to environmental cues, nutrient availability, and internal demands. These pathways, while tightly regulated under physiological conditions, often become dysregulated in disease states—most notably in cancer, where reprogramming of metabolism supports uncontrolled proliferation and resistance to therapy. The emergence of metabolism-targeted therapies, such as inhibitors of glycolysis, oxidative phosphorylation, and glutaminolysis, demonstrates the therapeutic value of disrupting specific metabolic circuits in diseased cells. This metabolic vulnerability opens a promising frontier in precision medicine, especially when combined with molecular diagnostics and biomarker-guided strategies.

The integration of multi-omics data, computational modeling, and synthetic biology is revolutionizing the way metabolic pathways are analyzed, manipulated, and utilized whether for clinical applications or industrial bioproduction. However, challenges such as metabolic redundancy, plasticity, and systemic toxicity must be addressed to fully harness the therapeutic potential of metabolic modulation. In essence, understanding and intervening in metabolic pathways is not merely a biochemical endeavor it is central to advancing next-generation diagnostics, disease treatment, and bioengineering solutions. As research continues to unfold, metabolism is poised to remain at the forefront of scientific innovation and translational breakthroughs.

Reference

1. Bajguz A, Piotrowska-Niczyporuk A. Biosynthetic pathways of hormones in plants. Metabolites. 2023;13(8):884. https://doi.org/10.3390/metabo13080884
2. Ayesha J, Michael SD; Metabolism. Essays Biochem. 2020;64(4):607-647. https://doi.org/10.1042/EBC20190041
3. Chandel NS. Basics of metabolic reactions. Cold Spring Harb Perspect Biol. 2021;13(8):a040527. https://doi.org/10.1101/cshperspect.a040527
4. Mesquita I, Rodrigues F. Cellular metabolism at a glance. Metabolic Interaction in Infection. 2018:3-27. https://doi.org/10.1007/978-3-319-74932-7_1
5. Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019;20(7):436-450. https://doi.org/10.1038/s41580-019-0123-5
6. Kumar R, Mishra A, Gautam P, Feroz Z, Vijayaraghavalu S, Likos EM, et al. Metabolic pathways, enzymes, and metabolites: opportunities in cancer therapy. Cancers. 2022;14(21):5268. https://doi.org/10.3390/cancers14215268
7. Cortassa S, Villon P, Sollott SJ, Aon MA. Integrated Multiomics, Bioinformatics, and Computational Modeling Approaches to Central Metabolism in Organs. InComputational Systems Biology in Medicine and Biotechnology: Methods and Protocols. 2022. 151-170p. https://doi.org/10.1007/978-1-0716-1831-8_7
8. Caspi R, Dreher K, Karp PD. The challenge of constructing, classifying, and representing metabolic pathways. FEMS Microbiol Lett. 2013;345(2):85-93. https://doi.org/10.1111/1574-6968.12194
9. Chandel NS. Glycolysis. Cold Spring Harbor Perspectives in Biology. 2021;13(5):a040535. https://doi.org/10.1101/cshperspect.a040535
10. Zois CE, Harris AL. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy. J Mol Med. 2016;94:137-154. https://doi.org/10.1007/s00109-015-1377-9
11. Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. 2020;37:101674. https://doi.org/10.1016/j.redox.2020.101674
12. Inigo M, Deja S, Burgess SC. Ins and outs of the TCA cycle: the central role of anaplerosis. Annu Rev Nutr. 2021;41(1):19-47. https://doi.org/10.1146/annurev-nutr-120420-025558
13. Zuo J, Tang J, Lu M, Zhou Z, Li Y, Tian H, et al. Glycolysis rate-limiting enzymes: novel potential regulators of rheumatoid arthritis pathogenesis. Front Immunol. 2021;12:779787. https://doi.org/10.3389/fimmu.2021.779787
14. Campos M, Albrecht LV. Hitting the sweet spot: how glucose metabolism is orchestrated in space and time by phosphofructokinase-1. Cancers. 2023;16(1):16. https://doi.org/10.3390/cancers16010016
15. Miller CG, Schmidt EE. Sulfur metabolism under stress. Antioxid Redox Signal. 2020;33(16):1158-1173. https://doi.org/10.1089/ars.2020.8151
16. Cadassou O, Jordheim LP. OXPHOS inhibitors, metabolism and targeted therapies in cancer. Biochem Pharmacol. 2023;211:115531. https://doi.org/10.1016/j.bcp.2023.115531
17. Greene J, Segaran A, Lord S. Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications. InSeminars in cancer biology 2022. 851-859p. https://doi.org/10.1016/j.semcancer.2022.02.002
18. Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, et al. Targeting glutaminolysis: new perspectives to understand cancer development and novel strategies for potential target therapies. Front oncol. 2020;10:589508. https://doi.org/10.3389/fonc.2020.589508
19. Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. InSeminars in cell & developmental biology 2020. 34-43p. https://doi.org/10.1016/j.semcdb.2019.05.012
20. Vo DK, Trinh KT. Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis. Int J Mol Sci. 2024;25(23):13190. https://doi.org/10.3390/ijms252313190
21. Kohli M, Poulogiannis G. Harnessing the Power of Metabolomics for Precision Oncology: Current Advances and Future Directions. Cells. 2025;14(6):402. https://doi.org/10.3390/cells14060402

https://doi.org/10.61577/jbs.2025.100004